SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-184952"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-184952" > Effects on insulin ...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003126naa a2200421 4500
001oai:DiVA.org:uu-184952
003SwePub
008121115s2012 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:125423604
024a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-1849522 URI
024a https://doi.org/10.1530/EJE-12-04842 DOI
024a http://kipublications.ki.se/Default.aspx?queryparsed=id:1254236042 URI
040 a (SwePub)uud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
100a Barner, C.4 aut
2451 0a Effects on insulin sensitivity and body composition of combination therapy with GH and IGF1 in GH deficient adults with type 2 diabetes
264 1c 2012
338 a print2 rdacarrier
520 a Objective: The aim of this trial was to evaluate the effect on insulin sensitivity and body composition of combination therapy with GH and IGF1 in adults with GH deficiency (GHD) and diabetes. Design, patients and methods: A 6-month randomised placebo-controlled pilot study. Fourteen adults with GHD and type 2 diabetes were included. All received rhGH (0.15 mg/day for 1 month and 0.3 mg/day for 5 months) and were randomised to rhIGF1 (15 μg/kg per day for 1 month and 30 μg/kg per day for 5 months) or placebo. Insulin sensitivity was evaluated with euglycaemic hyperinsulinaemic clamp and body composition by computed tomography of abdominal and thigh fat, as well as bioimpedance. Results: Twelve patients completed the study. They were overweight and obese; at baseline, insulin sensitivity (M-value) was low. IGF1 and IGF1 SDS increased in both groups, with the highest increase in the GH and IGF1 group. Positive changes in M-value by +1.4 mg/kg per min, in subcutaneous abdominal fat by -60.5 ml and in fat-free mass by +4.4% were seen in the GH and IGF1 group. Corresponding values in the GH and placebo-treated group were -1.5 mg/kg per min, +23 ml and -0.04% respectively (P=0.02, P=0.04 and P=0.03 for delta values between groups). No safety issues occurred. Conclusions: Combined GH and IGF1 treatment resulted in positive, but rather small effects, and might be a treatment option in a few selected patients.
653 a Growth-Factor-I
653 a Postmenopausal Women
653 a Replacement Therapy
653 a Hormone Deficiency
653 a Binding-Protein
653 a Glucose
653 a Metabolism
653 a Resistance
700a Petersson, M.u Karolinska Institutet4 aut
700a Engström, Britt Edénu Uppsala universitet,Endokrin diabetes och metabolism4 aut0 (Swepub:uu)brittee
700a Höybye, C.u Karolinska Institutet4 aut
710a Karolinska Institutetb Endokrin diabetes och metabolism4 org
773t European Journal of Endocrinologyg 167:5, s. 697-703q 167:5<697-703x 0804-4643x 1479-683X
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-184952
8564 8u https://doi.org/10.1530/EJE-12-0484
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:125423604

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy